Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(5):366-367; doi:10.1093/jnci/92.5.366
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nelson, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, N. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 5, 366-367, March 1, 2000
© 2000 Oxford University Press

NEWS

Can HER2 Status Predict Response to Cancer Therapy?

Nancy J. Nelson

In the field of HER2 research, there is overwhelming consensus on at least one point — that HER2 is a clinically important molecule. Peter M. Ravdin, M.D., Ph.D., of the University of Texas Health Science Center at San Antonio, opened up a National Cancer Institute conference on HER2 last October by saying that he feels that HER2 and the estrogen receptor are the two central molecules driving breast cancer therapy.

"Within the last couple of years, I think HER2 has emerged as a macromolecule that many of us now will be using for treatment planning," said Ravdin. "Both [HER2 and the estrogen receptor] are relevant to the growth of neoplasia. Both have prognostic implications. Both have been implicated in responsiveness to therapy, and both are targets for therapeutics," he said.

But agreement on the importance of . . . [Full Text of this Article]

HER2 Research

Future Studies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu
Effect of {gamma}-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene
J Natl Cancer Inst, November 2, 2005; 97(21): 1611 - 1615.
[Abstract] [Full Text] [PDF]